The "Cannabis Pharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for Cannabis Pharmaceuticals was estimated at US$5.2 Billion in 2024 and is projected to reach US$72.7 Billion by 2030, growing at a CAGR of 55.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Cannabis-based pharmaceuticals are emerging as a transformative segment within the global healthcare industry, driven by increasing scientific validation of cannabinoids for medical applications. The legalization of medical cannabis in numerous countries has fueled research and development (R&D) efforts, leading to the approval of cannabis-derived drugs for conditions such as epilepsy, multiple sclerosis, and chronic pain. Additionally, shifting regulatory frameworks and growing physician acceptance are paving the way for cannabis-based formulations to be integrated into mainstream healthcare.

What Are the Key Drivers Behind the Growth of the Cannabis Pharmaceuticals Market?

The growth in the cannabis pharmaceuticals market is driven by several factors, including expanding medical cannabis legalization, increased R&D investment, and growing patient demand for alternative treatments. Regulatory approvals for cannabis-based drugs in North America and Europe have legitimized the sector, encouraging pharmaceutical companies to develop new formulations. The opioid crisis has also contributed to the demand for non-addictive pain management solutions, positioning cannabis as a viable alternative.

Additionally, advancements in drug delivery systems and precision dosing are improving the efficacy of cannabis-based medications, further accelerating market growth. As global healthcare systems continue to recognize the benefits of medical cannabis, the pharmaceutical cannabis sector is poised for significant expansion.

How Are Advancements in Cannabis Research Expanding Pharmaceutical Applications?

Ongoing clinical research has uncovered the therapeutic potential of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC), leading to the development of prescription cannabis-based drugs. Pharmaceutical companies are investing in cannabinoid extraction and formulation technologies to enhance bioavailability, stability, and targeted delivery.

Advances in nanotechnology and encapsulation methods are improving the efficacy of oral, transdermal, and inhalable cannabis medications. Additionally, the exploration of minor cannabinoids such as cannabigerol (CBG) and cannabinol (CBN) is expanding the therapeutic scope of cannabis pharmaceuticals, potentially leading to new treatments for neurodegenerative diseases, anxiety disorders, and autoimmune conditions.

Which Therapeutic Areas Are Driving the Demand for Cannabis Pharmaceuticals?

The primary demand for cannabis-based pharmaceuticals comes from patients suffering from chronic pain, neurological disorders, and mental health conditions. Epidiolex, a CBD-based drug, has gained FDA approval for treating rare forms of epilepsy, while Sativex, an oral spray containing THC and CBD, is widely used for multiple sclerosis-related spasticity.

The growing acceptance of cannabis for pain management is leading to its adoption as an alternative to opioids, particularly for cancer and arthritis patients. Additionally, ongoing research into cannabis-based treatments for anxiety, PTSD, and sleep disorders is expanding the potential applications of cannabis pharmaceuticals.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Aphria Inc., Aurora Cannabis Inc., Bausch Health Companies Inc., Canopy Growth Corporation and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Sativex Brand segment, which is expected to reach US$52.6 Billion by 2030 with a CAGR of a 60.1%. The Epidiolex Brand segment is also set to grow at 49.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $1.4 Billion in 2024, and China, forecasted to grow at an impressive 51.8% CAGR to reach $10.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Scope of Study:

• Segments: Brand (Sativex Brand, Epidiolex Brand, Other Brands)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Influencer Market Insights
• Tariff Impact on Global Supply Chain Patterns
• Cannabis Pharmaceuticals - Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Growing Clinical Research Supporting Therapeutic Use of Cannabinoids
• Rising Acceptance of Cannabis-Derived Pharmaceuticals in Mainstream Medicine
• Expansion of Prescription-Based Cannabis Products Driving Market Maturity
• Advancements in Formulation Science Improving Bioavailability and Efficacy
• Increased Investment From Pharmaceutical Companies Accelerating Drug Development
• Emergence of Rare Cannabinoids Creating Opportunities for Niche Therapies
• Rising Demand for Chronic Pain and Neurological Disorder Treatments
• Integration of Cannabis Into Palliative and Cancer Care Expanding Patient Base
• Development of GMP-Compliant Manufacturing Facilities Elevating Product Standards
• Advancements in Drug Delivery Systems Enhancing Patient Compliance
• Consumer Shift Toward Plant-Based Medicine Driving Market Growth
• Increasing Healthcare Professional Education Enhancing Prescribing Confidence
• Digital Health Platforms Facilitating Cannabis-Based Treatment Accessibility
• Growth in International Medical Cannabis Programs Supporting Export Markets
• Focus on Standardized Dosing and Consistency Building Trust in Pharmaceutical Cannabis

FOCUS ON SELECT PLAYERS: Some of the 48 companies featured in this Cannabis Pharmaceuticals market report

• AbbVie Inc.
• Aphria Inc.
• Aurora Cannabis Inc.
• Bausch Health Companies Inc.
• Canopy Growth Corporation
• Cresco Labs Inc.
• Cronos Group Inc.
• Curaleaf Holdings, Inc.
• Green Thumb Industries Inc.
• GW Pharmaceuticals
• Harvest Health & Recreation Inc.
• Hexo Corp.
• Insys Therapeutics, Inc.
• Jazz Pharmaceuticals plc
• MedReleaf Corp.
• Organigram Holdings Inc.
• Sundial Growers Inc.
• Tilray Brands, Inc.
• Trulieve Cannabis Corp.
• VIVO Cannabis Inc.

For more information about this report visit https://www.researchandmarkets.com/r/hgjayb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250709261159/en/